Pharmafile Logo
Pharmafocus logo
Advanced Search

Amgen

Showing 15 posts of 216 posts found.

amgen_ucb

Amgen and UCB announce positive romosozumab results

February 22, 2016
Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …

News
amgen_flag

Amgen’s Kyprolis now available to UK multiple myeloma patients

February 12, 2016
Medical Communications, Sales and Marketing Amgen, Kyprolis, multiple myeloma

Amgen has announced the UK launch of Kyprolis (carfilzomib) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of …

News
sandoz_building

EMA accepts Sandoz Neulasta biosimilar for review

February 11, 2016
Research and Development Amgen, Neulasta, Novartis, Sandoz

Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …

News

NICE changes mind on Amgen’s cholesterol drug

February 8, 2016
Manufacturing and Production, Sales and Marketing Amgen, NICE, Repatha

NICE has changed its mind on Amgen’s cholesterol-busting drug Repatha (evolocumab), and decided to recommend approval of the treatment in …

News
Amgen image

FDA to review Amgen’s Humira biosimilar

January 26, 2016
Manufacturing and Production ABP-501, Amgen, FDA, biosimilar

The FDA has accepted for review Amgen’s Biologics License Application (BLA) for ABP 501, a biosimilar candidate to AbbVie’s Humira …

News

Amgen earns first Japanese nod for PCSK9 inhibitor

January 25, 2016
Sales and Marketing Amgen, Astellas, Japan, PCSK9 inhibitor, Repatha, evolocumab, high cholesterol

The Japanese Ministry of Health, Labour and Welfare has approved Amgen’s cholesterol-lowering medication Repatha, in a joint venture between Amgen …

News
Amgen image

FDA approves new Kyprolis combo for multiple myeloma

January 22, 2016
Medical Communications, Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma, myeloma

Amgen’s Kyprolis has been given another endorsement by the FDA as a multiple myeloma treatment – its second in six …

News
Baxalta logo

Baxalta’s Enbrel biosimilar measures up in late-stage study

January 13, 2016
Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis

Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …

News
Obama_SOTU

Big pharma joins President Obama’s cancer ‘moonshot’

January 13, 2016
Research and Development Amgen, Cancer, Celgene, National Immunotherapy Coalition, President Barack Obama, US, moonshot

Celgene and Amgen are among the large biopharma companies that have agreed to join the National Immunotherapy Coalition (NIC), a …

News
Imlygic

European approval for Amgen cancer drug Imlygic

December 18, 2015
Sales and Marketing Amgen, European Commission, Imlygic, melanoma, skin cancer, t-vec, talimogene laherparepvec

The European Commission has approved the use of Amgen’s Imlygic for adults with advanced melanoma, making it the first drug …

News
amgen_hq

Amgen buys back rights to three drugs from GSK

December 15, 2015
Research and Development, Sales and Marketing Amgen, GSK

Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …

News
Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

News
kyprolis_amgen

Amgen’s Kyprolis doubles Velcade benefit in head-to-head study

December 5, 2015
Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma

Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …

News
EU flag

Novartis and Amgen drugs signed-off by European Commission

November 24, 2015
Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto

The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …

News

NICE rejects Amgen’s Repatha in draft guidance

November 18, 2015
Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol

NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.   

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025